Intuit Inc. vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Intuit Inc. trades at $301.79 (market cap $81.21B), while Royalty Pharma plc Class A Ordinary Shares trades at $57.04 (market cap $25.27B). The key difference: Intuit Inc. is far larger — about 3.2× Royalty Pharma plc Class A Ordinary Shares's market cap, and Intuit Inc. pays the higher dividend (1.82%). Which is the better fit depends on your goals.
| INTU | RPRX | |
|---|---|---|
Market Cap | $81.21B | $25.27B |
Volume | 5,165,806 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $683.39 | $63.96 |
52-Week Low | $255.07 | $35.44 |
Enterprise Value | $82.43B | $32.50B |
Dividend Yield | 1.82% | 1.66% |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $297.24, up 2.56% today, with strong fundamentals including 21.29% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed moving averages, with key support at $293 and resistance at $300. Recent news highlights growth in QuickBooks monetization and AI initiatives, though overshadowed by multiple class action lawsuits filed in early September 2026.
Outlook remains positive with analyst consensus target of $379.68 (27.7% upside), supported by robust revenue growth and expanding margins. Key risks include legal overhang from securities litigation and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, but investors should monitor lawsuit developments and Q3 2026 earnings due soon.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →